MicroRNA-665 Regulated Cell Proliferation, Migration and Apoptosis by Targeting Nemo-like Kinase in Non-small Cell Lung Cancer

doi:10.21203/rs.3.rs-51046/v1

Download PDF

Research article

MicroRNA-665 Regulated Cell Proliferation, Migration and Apoptosis by Targeting Nemo-like Kinase in Non-small Cell Lung Cancer

https://doi.org/10.21203/rs.3.rs-51046/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background: Many evidences proved important roles of microRNAs in the occurrence and development of non-small cell lung cancer (NSCLC). This work aimed to explore the effects and regulating mechanism of microRNA-665 (miR-665) in NSCLC.

Methods: Here, quantitative real time PCR was used to evaluate the expression level of miR-665 in NSCLC tissues and several cell lines (H520, H1299, PC9, H358, and A549). Then, MTT, apoptosis assays and wound-healing assays were performed to study miR-665 functions on cell proliferation, apoptosis and migration. Based on bioinformatics analysis, nemo-like kinase (NLK) was predicted as a potential target of miR-665 and then a series of experiments were performed to explore miR-665 mechanism.

Results: In NSCLC tissues and several cell lines, miR-665 was up-regulated and cell experiments displayed that it had abilities to promote cell proliferation and migration, and inhibit cell apoptosis. MiR-665 over-expression could reduce NLK mRNA and protein level by binding to 3′-untranslated region of NLK, which suggested that miR-665 could regulate NLK expression. Further analysis found that there was an inverse correlation f between miR-665 and NLK in NSCLC. Moreover, low-level NLK possessed same effects on cells as miR-665 over-expression, and its knockdown could partly recovery the miR-665-mediated cell proliferation, migration and anti-apoptosis, indicating that miR-665 might regulate biological behaviors of NSCLC cells via targeting NLK.

Conclusion: MiR-665 probably promoted NSCLC occurrence and progression via targeting NLK, which might be a hopeful biomarker for NSCLC diagnosis or a target for treatment.

Cancer Biology

Oncology

MicroRNA-665

Non-small cell lung cancer

Nemo-like kinase

Oncogene

At present, lung cancer has been a great threat to both men and women, which caused about 1.5 million deaths in global annually [1, 2]. The main variables linked with the incidence and progression of lung cancer cover smoking, hormonal imbalance, various epigenetic and genetic mutations, and high exposure to environmental pollutants [2, 3]. On the basis of histological features, lung cancer can be divided into small cell (SCLC) and non-small cell lung cancers (NSCLC), and NSCLC accounted for more than 85% of patients with lung cancer [4]. NSCLC has several predominant subtypes such as adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma, which primarily evolve from the epithelial cell lining. Compared to small cell carcinoma, NSCLCs are insensitive to chemotherapy [5]. In addition, high recurrence rate, early formation of micro-metastases, and some problems in detection and diagnosis also lead to poor prognosis and low 5-year survival rate (less than 20% in total) in all lung cancers [2, 6]. To enhance the detection, diagnosis and treatment of lung cancer, many methods have been improved or developed, including various imaging technologies (such as X-ray, computed tomography, and positron emission tomography), nanoparticle systems, biomarkers and treat targets. Among them, the identification of biomarkers was considered as a promising way to improve cancer diagnosis and detection. Recently, food and drug administration in US has approved several biomarkers in the detection and diagnosis of lung cancer. In 2004, carcinoembryonic antigen as a protein biomarker has been approved for lung cancer diagnosis. Unfortunately, it has poor effect and it has better to be combined with other biomarkers (such as cytokeratin fragment-21) [7, 8]. Thus, more biomarkers were necessary for more accurate detection of lung cancer, particularly early stage.

In clinic, the biomarkers used for lung cancer detection, include tumor infiltrating lymphocytes, cell-free DNA (cfDNA), autoantibodies, microRNAs (miRNAs) and so on [9–12]. Among them, miRNAs are considered as important players in many biological processes and linked with pathological parameters of various cancers, such as ovarian cancer, liver cancer and colorectal cancer, implying their potential as cancer biomarkers [13–15]. In lung cancer, some studies disclosed that many miRNAs displayed 92–100% specificity and 75–85% sensitivity in differentiation between lung cancer and normal samples [2, 16]. Moreover, expression regulation of miRNAs probably was linked with the occurrence and progression of lung cancer. For instance, miR-4735-3p and miR-183-5p were over-expressed in NSCLC tissues and cell lines, while miR-143 and miR-520a-3p were down-regulated in lung cancer [17–20]. Nevertheless, the regulatory mechanism of miRNAs is still exploring in lung cancer and other cancers. It was generally accepted that the miRNAs possibly regulated expression of target genes in tumors by blocking or degrading mRNA molecules of target genes [21, 22]. More works need to be done to deeply understand their mechanism, especially NSCLC.

MicroRNA-665 (miR-665), an exosomal miRNA, has been found that it is associated with different diseases, like congestive heart failure [23], anesthesia-related cognitive dysfunction [24], inflammatory bowel disease [25], and cancer [26]. Interestingly, miR-665 showed different functions for different diseases. For examples, miR-665 upregulation promoted cell apoptosis and colitis in inflammatory bowel disease through suppressing the endoplasmic reticulum stress components XBP1 and ORMDL3; while its high-expression could promote tumor growth and cell proliferation in hepatocellular carcinoma by increasing the expression of proteins in the MAPK/ERK pathway [25, 26]. However, its effects on NSCLC have not been reported. The key purpose of this work was to explore miR-665 roles and possible mechanism in NSCLC. Firstly, quantitative real time PCR (q RT-PCR) was performed to measure the expression level of miR-665 in NSCLC tissues and cell lines. Then, we constructed cells that could stably over-express and low-express miR-665 by cell transfection, and then studied its functions on cell proliferation, migration and apoptosis. Finally, prediction software was used to obtain a potential target of miR-665 and further experiments were carried out to verify it.

2.1 Specimen collection

This research has been approved by the Ethics Committee of Qilu Hospital, Cheeloo College of Medicine, Shandong University, and each patient participating in this study has signed the written informed consent. We collected 38 pairs of NSCLC tissues and corresponding normal lung tissues from patients who were diagnosed with NSCLC based on histopathological evaluation and undergone surgery at this hospital during 2015–2017. In addition, none patients had treated by radiotherapy or chemotherapy before surgery. All tissue specimens were flash-frozen in liquid nitrogen and preserved at -80°C.

2.2 Cell culture and transfection

The normal human bronchial epithelioid cell line (BEAS-2B) and human NSCLC cell lines H520 (from squamous cell lung cancer tissue with low-level p53 mRNA), H1299 (epithelial cell from fymphatic metastasis without p53 protein), PC9 (Human lung adenocarcinoma erlotinib resistant cells), H358 (epithelial cell from tumor tissue with expressing protein and RNA of SP-A), and A549 (epithelial cell from tumor tissue) were obtained from the Qilu Hospital, Cheeloo College of Medicine, Shandong University,. BEAS-2B was cultured in Dulbecco’s modified Eagle medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% penicillin/streptomycin/gentamicin (Invitrogen). A549 and H358 were cultured in DMEM-F12 (Invitrogen, Carlsbad, CA, USA) containing 10% FBS and 1% penicillin/streptomycin/gentamicin. H520, H1299 and PC9 were cultured in RPMI 1640 (Invitrogen) including 10% FBS and 1% penicillin/streptomycin/gentamicin. All cells were cultured in a humidified incubator at 37°C with 5% CO₂. The miR-665 mimic, inhibitor, mimic negative control (mimic NC), negative control (inhibitor NC) and shnemo-like kinase (NLK) oligo were obtained from GenePharma (Shanghai, China) and transfected into H358 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The each RNA concentration used for cell transfection was 50 nM.

2.3 QRT-PCR

Total RNA of cells or tissues was obtained using the TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. Then, the RNA was used to synthesize cDNA by reverse transcriptase M-MLV (Takara, Dalian, China) following the manufacturer’s instruction to synthesize cDNA. Q RT-PCR tests were performed using the standard SYBR Green Assay protocol and the ABI PRISM 7500 Sequence Detection System (ABI). The reaction conditions were as below: pre-denaturation at 95 °C for 10 min, denaturation at 95 °C for 10 s, renaturation at 60 °C for 60 s, and extension at 70 °C for 10 s. Q RT-PCR had a total of 40 cycles. The primers were as follows: miR-665, forward: 5’-ACCAGGAGGCTGAGGCCCCTAA-3’, reverse: 5’-GCTGTCAACGATACGCTACCTA-3’; NLK, forward: 5’-ATCATCAGCACTCGCATCATC-3’, reverse: 5’-GACCAGACAACACCAAAGGC-3’. U6 snRNA was used as a normalization control of miR-665. Lactate dehydrogenase A (LDHA) was also analyzed by q RT-PCR using SYBR Premix Ex Taq (TaKaRa) and GAPDH acted as internal control. Cycle threshold (Ct) of each gene was recorded and applied to calculate the relative expression of genes as per 2^− ΔΔCt method.

2.4 Cell proliferation assay

Cell proliferation assay was performed according to MTT method. H358 cells (1 × 10³ cells per well) were plated into 96-well plates after transfection. At the indicated time points (1, 2, 3, and 4 day), 50 µL MTT (2 mg/mL; Keygen, China) solution was added into each well and the cells were incubated for 4 h at 37 °C. After that, the culture medium was removed and 150 µL DMSO was added into wells. The optical density (OD) of each well at 550 nm was measured in a Tecan Infinite Multiskan (Tecan, Swiss).

2.5 Cell apoptosis assay

H358 cells (1 × 10⁵ cells) were seeded into 6-well plates and transfected with miR-665 mimic/inhibitor or mimic NC/inhibitor NC. After 48 h transfection, cells were harvested and resuspended in 500 µL binding buffer. Then cell suspension was incubated with 5 µL Annexin V-FITC for 15 min in the dark, following 5 µL of PI (50 µg/mL) was added to each sample. Finally, flow cytometry (C6; BD Biosciences, Franklin Lakes, NJ, USA) was used to determine apoptosis of the H358 cells.

2.6 Wound healing assays

The migration ability of NSCLC cells was investigated by wound healing assays. After 48 h cell transfection, H358 cells were plated in 24 well plates at a density of 8 × 10⁴ cells/well and cultured until they formed a confluent monolayer. Wounds were scratched by 10 µL pipette tips. Then, each well was washed 3 times with phosphate-buffered saline (PBS) and added serum-free medium. QImagine Software was used to photograph each well every 12 h.

2.7 Luciferase reporter assay

The 3′-UTR of nemo-like kinase (NLK) mRNA, containing a putative target region for miR-665, was amplified from genomic DNA by PCR. The mutant of NLK 3′-UTR was constructed by overlap extension PCR. Then, fragments obtained were inserted between the XhoI and NotI sites in the psiCHECK™-2 Dual Luciferase miRNA target expression vector (Promega, USA) to produce the recombinant vectors of NLK-wide type (NLK-WT) and NLK-mutant type (NLK-MT). Both recombinant vectors were detected by sequencing (Sangon, China). The reporter vectors and miR-665 mimic/mimic NC was co-transfected into H358 cells using Lipofectamine 2000. After 48 h co-transfection, luciferase activity of each group was detected using the Dual Luciferase Reporter Assay Kit (Promega, USA) based on the direction.

2.8 Western blotting

Cells were firstly washed twice using Hanks’ balanced salt solution and lysed in RIPA lysis buffer (50 mM Tirs-Cl, pH 7.4, 120 mM NaCl, 1% NP-40, 0.2% SDS, 1 mM EDTA and complete protease inhibitor), following centrifuged at 4 °C for 20 min with 13,000 g. Subsequently, the protein concentration was tested by a BCA Protein Assay Kit (Beyotime, China) based on the instructions. Next, 20 µg of protein were denatured using 4 × loading buffer (Takara, Japan) at 95 °C for 5 min. Equal quantities of protein were separated via electrophoresis using 10% SDS polyacrylamide gel, and then transferred onto polyvinylidene difluoride (Life Technologies, USA) membranes. The membranes were firstly washed by PBS and blocked with 5% non-fat milk. Then, the membranes were incubated with anti-NLK (1:500; Abcam, UK, ab97642) and anti-GAPDH (1:2000; Abcam, UK, ab9485) at 4 °C overnight. After the membranes were washed three times with PBS containing 5% Tween (Sigma-Aldrich), they were incubated with horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody at room temperature for 2 h. An ECL kit was used to visualize the protein bands according to the manufacturer’s instructions. The relative protein expression levels were analyzed using Image-ProPlus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA).

2.9 Statistical analysis

All data were analyzed via SPSS 17.0 software and expressed as mean ± standard deviation. The independent-samples t-test was used for the comparison between two groups, and the analysis among more than two groups was performed using the one-way ANOVA test, followed by Bonferroni’s post-hoc test. If P < 0.05, the results were statistically significant.

3.1 MiR-665 was greatly up-regulated in NSCLC tissues and cell lines

To confirm whether miR-665 had abnormal expression in NSCLC, we firstly performed q RT-PCR to detect the expression level of miR-665 in 38 pairs of NSCLC tissues and adjacent normal lung tissues. Figure 1A showed that the level miR-665 was significantly higher in an independent panel of 38 primary lung tumors than that in normal matched lung tissue (P < 0.01). Subsequently, we determined an average of 2.0546 based on the relative miR-665 expression level. NSCLC patients were divided into high expression group (≥ 2.0546, n = 18) and low expression group (< 2.0546, n = 20) based on the average miR-665 expression in 38 samples. Moreover, to assess the clinical significance of miR-665, we evaluated the correlation between expression level and clinicopathological parameters. Table 1 displayed that miR-665 expression was closely associated with smoking history, while it was not linked to other clinical risk factors including age, gender, tumor type and differentiation, T-classification, and lymphatic metastasis (*P < 0.05). We then explored miR-665 expression levels in five NSCLC cell lines (H520, H1299, PC9, H358, and A549). Figure 1B revealed that miR-665 had higher level in four NSCLC cell lines (A549, H358, H1299 and PC9) than that in BEAS-2B (*P < 0.05, **P < 0.01), while there was no significant difference between H520 and BEAS-2B (*P > 0.05). These results indicated that the expression of miR-665 was up-regulated in NSCLC, which might have roles on NSCLC progression.

Table 1

Correlation between miR-665 expression and clinicopathological parameters of NSCLC (n = 38)
Characteristics	Number (n = 38)	miR-665 expression		P value
Characteristics	Number (n = 38)	High (n = 18)	Low (n = 20)	P value
Age ≤60 >60
	18	7	11	0.321
	20	11	9	0.321
Gender Male Female
	29	13	16	0.573
	9	5	4	0.573
Smoking history Yes No
	15	11	4	0.010^*
	23	7	16	0.010^*
Type SCC ADC
	23	10	13	0.552
	15	8	7	0.552
Differentiation Poor Well or moderate
	21	9	12	0.536
	17	9	8	0.536
T-classification T1-T2 T3-T4
	23	11	12	0.944
	15	7	8	0.944
N- classification N0 N1-N3
	17	7	10	0.492
	21	11	10	0.492
Clinical Stage I-II III-IV
	22	9	13	0.350
	16	9	7	0.350
^*P < 0.05. ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma.

3.2 MiR-665 enhanced proliferation and migration ability of NSCLC cells and inhibited cell apoptosis

In order to explore the underlying functions of miR-665 in NSCLC development and progression, H358 cells were transfected by miR-665 mimic, inhibitor and their corresponding negative control oligonucleotides to regulate miR-665 expression, and q RT-PCR results (Fig. 2A, B) displayed that miR-665 mimic significantly increased the level of miR-665 while its inhibitor reduced its expression, suggesting cell transfection was successfully done (**P < 0.01). Then, MTT, wound-healing assay and FACS analysis were respectively performed to study the roles of miR-665 on cell proliferation, migration and apoptosis in H358 cells. As shown in Fig. 2C, cells transfected with miR-665 mimic showed significantly higher OD values at 550 nm from day 2 to day 4 in a time dependent manner (**P < 0.01). However, the miR-665 inhibitor group displayed lower OD values (Fig. 2D) implying that cell proliferation was suppressed (*P < 0.05, **P < 0.01). Figure 3A and B showed that overexpression of miR-665 significantly promoted cell migration (*P < 0.05), while its down-regulation had opposite effect (**P < 0.01). As shown in Fig. 4A and B, cell apoptosis was significantly inhibited in miR-665 mimic group compared with NC group (**P < 0.01) and miR-665 inhibitor group had higher apoptosis rate (**P < 0.01), which suggested that miR-665 may affect apoptotic pathways in regulating tumorigenicity. The above results suggested that miR-665 upregulation could promote the cell proliferation and migration, and inhibit cell apoptosis for NSCLC cells in vitro.

3.3 NLK was a novel target gene of miR-665 in H358 cells

To find the underlying mechanisms of miR-665 in NSCLC, we investigated potential targets of miR-665 using prediction software (TargetScan, PicTa, miRanda, the miRBase, DIANA TarBase). Bioinformatic analyses predicted that NLK was a potential target of miR-665 (Fig. 5A). To validate whether miR-665 might mediate the decay of NLK mRNA via the 3′-UTR, we generated NLK-WT and NLK-MT vectors, and these recombinant vectors were transfected into H358 cells with miR-665 mimic or NC miRNA. Figure 5B showed that miR-665 overexpression remarkably down-regulated the luciferase activity of the NLK-WT group (**P < 0.01), while it was not influenced the luciferase activity in NLK-MT group (*P > 0.05). As shown in Fig. 5C and D, mRNA and protein levels of NLK were significantly decreased in miR-665 mimic group compared to NC group (**P < 0.01). Furthermore, NLK was low-regulated in NSCLC tissues and there was a negative correlation between NLK and miR-665 (Fig. 5E and F). These data demonstrated that miR-665 could down-regulate NLK expression by directly targeting NLK 3′-UTR.

3.4 MiR-665 regulated cell growth, migration and apoptosis of NSCLC cells by targeting NLK

H358 cells were transfected with NLK shRNA or NC shRNA to further investigate whether the effect of miR-665 on NSCLC cells was via targeting NLK. Figure 6A showed that the three kinds of NLK shRNA could obviously decrease the relative mRNA level of NLK, implying successful transfection (**P < 0.01). As shown in Fig. 6B, the OD value in H358 cells transfected with NLK shRNA was significantly higher than those transfected with NC shRNA after transfection 2 days (*P < 0.05, **P < 0.01). Figure 6C and D indicated that suppressing NLK expression by shRNA could promote cell migration and inhibit cell apoptosis (**P < 0.01). From the above, our findings suggested that miR-665 promoted cell growth, migration and inhibited apoptosis of NSCLC cells, at least in part by targeting NLK.

3.5 Interference of NLK partly restored miR-665-mediated proliferation and migration of NSCLC cell

Finally, to deeply verify the mechanism of miR-665 in NSCLC cells, the NLK-targeting shRNA oligo were employed to deplete endogenous NLK in NSCLC cells. NC, miR-665 inhibitor and NLK shRNA oligo were transfected independently or simultaneously into H358 cells. As shown in Fig. 7A and B, depletion of NLK induced by transfection of NLK shRNA could obviously promote cell proliferation and migration (*P < 0.05, **P < 0.01), and miR-665 inhibitor weakened them, compared with NC group. However, cell proliferation and migration abilities were partly improved in cells co-transfected with miR-665 inhibitor and NLK shRNA, compared to the cells only transfected with miR-665 inhibitor (**P < 0.01).In Fig. 7C, the result of FACS analysis exhibited that the transfection of NLK shRNA could obviously reduce cell apoptotic (**P < 0.01), and the NLK shRNA weakened the roles on apoptotic caused by miR-665 inhibitor in some degree, indicating that depletion of NLK could partly recovery the miR-665-mediated anti-apoptotic effect. Based on all data, we inferred that miR-665 probably regulated cell proliferation, migration and apoptosis in NSCLC by manipulating NLK expression.

As one of the most common malignancy, lung cancer has become a leading cause of cancer-related death worldwide, and its morbidity and mortality come out in front in various malignant tumors [27]. NSCLC account for nearly 80% cases and every year more than thousands of patients were diagnosed with NSCLC. In clinical, the delay of detection and diagnosis for NSCLC patients are a serious problem. At present, most patients were diagnosed in locally advanced or metastatic stages, while only 16% of them were detected before malignancy [28]. In addition, the survival time of patients with NSCLC at early stages was much longer than those at late stage [29]. Moreover, because NSCLC showed insensitivity to chemotherapy, therapeutic outcomes were worse and the patients had poorer prognosis [5]. Thus, to identify potential biomarkers for NSCLC is quite essential, which will contribute to improve detection and therapeutic strategy in clinical management. MiRNAs, containing 19 to 25 nucleotides, play important roles in cell growth, proliferation and apoptosis, which makes it exert as oncogenes or anti-oncogenes in different tumors. Various miRNAs have been considered as potential specific biomarker for cancers, for example, miR-21 showed 100% speciﬁcity and 70% sensitivity in NSCLC cases and it was related with aggressive clinicopathologic characteristics and poor prognosis of NSCLC patients [31, 32]. Thus, searching potential miRNA in NSCLC was good strategy.

Previous papers reported that miR-665 possessed different functions in different diseases. For examples, it had neuroprotective effect against sevoflurane anesthesia-induced cognitive dysfunction, and it promoted apoptosis and colitis in inflammatory bowel disease [24, 25]. However, the expression level and effects of miR-665 in NSCLC were still unclear. In this work, we mainly studied the effects and possible mechanism of miR-665 in NSCLC. The results of q RT-PCR showed that it was up-regulated in NSCLC tissues and four cell lines (A549, H358, H1299 and PC9), implying that it might be a candidate gene used for NSCLC diagnosis. The further experiments exposed that miR-665 over-expression could promote cell proliferation and migration and inhibit apoptosis for NSCLC cells in vitro. Recent paper reported that miR-665 was increased in hepatocellular carcinoma and it possessed promoting ability on tumor growth and cell proliferation [26]. Our results were consistent with their, suggested that miR-665 might act as oncogenes in cancers and have close relationships with occurrence and progression of cancers.

Many studies have proved that there were close relationships between miRNAs and cancers, but the mechanism needed more researches. Some experiments displayed that miRNAs could acts as post-transcriptional regulators to regulate gene expression via binding to 3′-untranslated region (3′-UTR) of their target mRNAs [23, 30]. Then, we used prediction software to obtain a potential target of miR-665—NLK. Luciferase reporter assay displayed that miR-665 might promote decay of NLK mRNA by base-pairing to the 3′-UTR of NLK. The results of q RT-PCR and western blot showed that miR-665 up-regulation could significantly reduce the mRNA and protein level of NLK, proving that miR-665 might regulate NLK expression by targeting 3′-UTR. Moreover, suppression NLK could enhance proliferation and migration ability, while weaken cell apoptosis. To verify whether miR-665 played roles on cancer cells by regulating NLK, MTT, wound healing and flow cytometry assays were performed after H358 cells were transfected with NLK shRNA, miR-665 inhibitor, or miR-665 inhibitor + NLK shRNA. The data showed that depletion of NLK could restore miR-665-mediated proliferation, migration and anti-apoptotic functions for NSCLC cells in part.

This work found that miR-665 was up-regulated in NSCLC tissues and cell lines (A549, H358, H1299 and PC9), and it mediated proliferation, migration and anti-apoptotic in NSCLC probably by targeting NLK, suggesting that miR-665 might exert as an oncogene in NSCLC. In addition, miR-665 was hopeful to be a potential biomarker for NSCLC diagnosis or a new target for NSCLC treatment.

non-small cell lung cancer:NSCLC; small cell: SCLC; nemo-like kinase: NLK; cell-free DNA: cfDNA; quantitative real time PCR: q RT-PCR

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Xinxiang Central Hospital. The research has been carried out in accordance with the World Medical Association Declaration of Helsinki. All patients and healthy volunteers provided written informed consent prior to their inclusion within the study.

Consent for publication

All authors have read and approved the final manuscript.

Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Competing interests

There was no any conflict of interest.

Funding

This work was supported by National Natural Science Foundation (Grant No. 81672292) and TaiShan Scholar Program of Shandong Province (Grant No. ts201712087).

Authors contribution

CH and HT concept, study design, experiments, manuscript preparation. CH, WMY, LL, SHL, CG, LQ, CLC, ML and LBS experiments, data analysis, manuscript preparation. All authors have read and approved the manuscript.

Acknowledgement

Not applicable

Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 2016 (2016) 1823–1833.
Roointan A, Mir TA, Wani SI, et al. Early detection of lung cancer biomarkers through biosensor technology: A review. J Pharm Biomed Anal. 2019;164:93–103.
MacKinnon AC, Kopatz J, Sethi T. The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. Br Med Bull. 2010;95:47–61.
Barash O, Peled N, Hirsch FR, Haick H. Sniffing the Unique “Odor Print” of Non-Small-Cell Lung Cancer with Gold Nanoparticles. Small. 2009;5:2618–24.
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010;362(25):2380–8.
Hashim D, Weiderpass E. Cancer Survival and Survivorship. Encyclopedia of Cancer (Third Edition). 2019;1:250–9.
Kawachi R, Suzuki K, Kunitoh H, et al. Prognosis of lung cancer patients with high preoperative carcinoembryonic antigen (CEA) level: Are they surgical candidates. J Clin Oncol. 2004;22:7181–1.
Ruiz-Ceja KA, Chirino YI. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomed Pharmacother. 2017;90:24–37.
Zeng DQ, Yu YF, Ou QY, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget. 2016;7:13765–81.
Sozzi G, Boeri M. Potential biomarkers for lung cancer screening. Transl Lung Cancer Res. 2014;3:139.
Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008;63:228–33.
Barger JF, Nana-Sinkam SP. MicroRNA as tools and therapeutics in lung cancer. Respir Med. 2015;109:803–12.
Loginov VI, Pronina IV, Burdennyy AM, et al. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis. Gene. 2018;662:28–36.
Liu Z, Sun J, Liu B, et al. MiRNA-222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. Int J Mol Med. 2018;42(1):141–8.
Jia W, Yu T, An Q, Cao X, Pan H. MicroRNA-423-5p inhibits colon cancer growth by promoting caspase-dependent apoptosis. Exp Ther Med. 2018;16(2):1225–31.
Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011;11:374.
Wang D, Han X, Li C, Bai W. FBXL3 is regulated by miRNA-4735-3p and suppresses cell proliferation and migration in non-small cell lung cancer. Pathol Res Pract. 2019;215:358–65.
Wang H, Ma Z, Liu X, et al. MiR-183-5p is required for non-small cell lung cancer progression by repressing PTEN. Biomed Pharmacother. 2019;111:1103–11.
Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–98.
Yu J, Tan Q, Deng B, et al. The microRNA-520a-3p inhibits proliferation, apoptosis and metastasis by targeting MAP3K2 in non-small cell lung cancer. Am J Cancer Res. 2015;5(2):802–11.
D.P. Bartel. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. (2004) 281–297.
Iorio M, Croce C. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18(3):215–22.
MöHnle P, Schütz SV, Schmidt M, et al. MicroRNA-665 is involved in the regulation of the expression of the cardioprotective cannabinoid receptor CB2 in patients with severe heart failure. Biochem Biophys Res Commun. 2014;451(4):516–21.
Lu X, Lv S, Mi Y, et al. Neuroprotective effect of miR-665 against sevoflurane anesthesia-induced cognitive dysfunction in rats through PI3K/Akt signaling pathway by targeting insulin-like growth factor 2. Am J Transl Res. 2017;9(3):1344–56.
Li M, Zhang S, Qiu Y, et al. Upregulation of miR-665 promotes apoptosis and colitis in inflammatory bowel disease by repressing the endoplasmic reticulum stress components XBP1 and ORMDL3. Cell Death Dis. 2017;8(3):e2699.
Qu Z, Wu J, Wu J, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis. Oncotarget. 2017;8(46):80666–78.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
Barash O, Peled N, Hirsch FR, Haick H. Sniffing the Unique “Odor Print” of Non-Small-Cell Lung Cancer with Gold Nanoparticles. Small. 2009;5:2618–24.
Siegel R, Miller K, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
Li W, Cui Y, Wang D, Wang Y, Wang L. MiR-141-3p functions as a tumor suppressor through directly targeting ZFR in non-small cell lung cancer. Biochem Biophys Res Commun. 2019;509:647–56.
Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67:170–6.
Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008;54:1696–704.

renamedee84c.jpg

Download PDF

Version 1

posted

You are reading this latest preprint version

MicroRNA-665 Regulated Cell Proliferation, Migration and Apoptosis by Targeting Nemo-like Kinase in Non-small Cell Lung Cancer

Status:

Version 1

Abstract

Figures

1. Background

2. Methods

2.1 Specimen collection

2.2 Cell culture and transfection

2.3 QRT-PCR

2.4 Cell proliferation assay

2.5 Cell apoptosis assay

2.6 Wound healing assays

2.7 Luciferase reporter assay

2.8 Western blotting

2.9 Statistical analysis

3. Results

3.1 MiR-665 was greatly up-regulated in NSCLC tissues and cell lines

3.2 MiR-665 enhanced proliferation and migration ability of NSCLC cells and inhibited cell apoptosis

3.3 NLK was a novel target gene of miR-665 in H358 cells

3.4 MiR-665 regulated cell growth, migration and apoptosis of NSCLC cells by targeting NLK

3.5 Interference of NLK partly restored miR-665-mediated proliferation and migration of NSCLC cell

4. Discussions

Conclusions

Abbreviations

Declarations

Ethics approval and consent to participate

Consent for publication

Availability of data and materials

Competing interests

Funding

Authors contribution

Acknowledgement

References

Supplementary Files

Status:

Version 1